论文部分内容阅读
目的:对肾康注射液(SKI)治疗急性肾衰竭的临床价值进行研究分析。方法:从我院急性肾衰竭患者中选取48例进行研究分析,并按照患者临床治疗方法将其分为治疗组(采用肾康注射液治疗)和对照组(采用常规治疗方法治疗),均24例,对比两组患者临床治疗总有效率、治疗前后Scr和血Cys C水平。结果:治疗组患者临床治疗总有效率高达83.33%同对照组患者的58.33%相比,P<0.05;治疗前,两组患者Scr和血Cys C水平没有显著差异性,P>0.05;治疗后,两组患者Scr和血Cys C水平显著低于治疗前的,且治疗组患者低于对照组患者的,P<0.05。结论:在治疗急性肾衰竭的临床上肾康注射液临床效果显著,其对患者正常生活具有良好改善作用。
Objective: To study the clinical value of Shenkang injection (SKI) in the treatment of acute renal failure. Methods: Forty-eight patients with acute renal failure in our hospital were studied and analyzed, and were divided into treatment group (treated with Shenkang injection) and control group (treated by conventional treatment) according to the clinical treatment of patients, 24 Cases, compared the total effective rate of two groups of patients with clinical treatment, before and after treatment Scr and blood Cys C levels. Results: The total effective rate of clinical treatment was 83.33% in treatment group compared with 58.33% in control group (P <0.05). Before treatment, there was no significant difference in Scr and Cys C between the two groups (P> 0.05) . The levels of Scr and Cys C in both groups were significantly lower than those before treatment, and those in the treatment group were lower than those in the control group (P <0.05). Conclusion: The clinical effect of Shenkang injection in the treatment of acute renal failure is remarkable, which has a good effect on the normal life of patients.